Viamet is a clinical-stage infectious disease company that discovers and develops novel, small molecule therapies for the treatment of human fungal infections.

Viamet is a biopharmaceutical company focused on the discovery, development and commercialization of novel antifungal agents based on our proprietary metalloenzyme medicinal chemistry platform, which we call our Metallophile® Technology. We are using this platform to design drugs that we expect to have greater selectivity, fewer side effects and improved potency compared to currently available antifungal agents. Our lead product candidate, VT-1161, is an oral agent that we are developing for the treatment of recurrent vulvovaginal candidiasis, or RVVC, a highly prevalent mucosal infection for which there are no approved therapies in the United States, and onychomycosis, a very common fungal infection of the nail for which current treatments are suboptimal with respect to safety, tolerability and efficacy. Our pipeline also includes preclinical programs that we are developing to treat life-threatening invasive fungal diseases.

Latest News

September 11, 2014
Viamet Receives Orphan Drug Designation for VT-1129
September 10, 2014
Data for Viamet's VT-1161 Presented at ICAAC 2014

Our Company

We are using our Metallophile Technology® to design antifungal compounds that we believe will be highly differentiated from existing agents and address their shortcomings. The focus of our three principal antifungal programs is a metalloenzyme known as fungal CYP51, a clinically validated target that is important in the synthesis of the fungal cell membrane and therefore critical to fungal proliferation and survival. Our Metallophile Technology® is also potentially applicable to other metalloenzyme targets for the treatment of fungal, bacterial and viral infections.